Pluri Inc. (PLUR)
NASDAQ: PLUR · IEX Real-Time Price · USD
5.55
+0.11 (1.98%)
At close: Jul 19, 2024, 4:00 PM
5.64
+0.09 (1.67%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Pluri Revenue
Pluri had revenue of $341.00K in the twelve months ending March 31, 2024, with 93.75% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $71.00K. In the fiscal year ending June 30, 2023, Pluri had annual revenue of $287.00K with 22.65% growth.
Revenue (ttm)
$341.00K
Revenue Growth
+93.75%
P/S Ratio
87.67
Revenue / Employee
$2,545
Employees
134
Market Cap
29.89M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 287.00K | 53.00K | 22.65% |
Jun 30, 2022 | 234.00K | - | - |
Jun 30, 2021 | 0 | - | - |
Jun 30, 2020 | 23.00K | -31.00K | -57.41% |
Jun 30, 2019 | 54.00K | 4.00K | 8.00% |
Jun 30, 2018 | 50.00K | - | - |
Jun 30, 2017 | 0 | - | - |
Jun 30, 2016 | 2.85M | 2.47M | 651.19% |
Jun 30, 2015 | 379.00K | - | - |
Jun 30, 2014 | 379.00K | -300.00K | -44.18% |
Jun 30, 2013 | 679.00K | -37.00K | -5.17% |
Jun 30, 2012 | 716.00K | - | - |
Jun 30, 2011 | 0 | - | - |
Jun 30, 2010 | 0 | - | - |
Jun 30, 2009 | 0 | - | - |
Jun 30, 2008 | 0 | - | - |
Jun 30, 2007 | 0 | - | - |
Jun 30, 2006 | 0 | - | - |
Jun 30, 2005 | 0 | - | - |
Jun 30, 2004 | 0 | - | - |
Jun 30, 2003 | 0 | - | - |
Jun 30, 2002 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CareCloud | 113.02M |
Rapid Micro Biosystems | 23.10M |
Streamline Health Solutions | 21.59M |
Spectral AI | 19.30M |
Evogene | 9.19M |
Lipocine | 4.71M |
Daré Bioscience | 2.82M |
PLUR News
- 4 days ago - Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates - GlobeNewsWire
- 4 weeks ago - Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges - GlobeNewsWire
- 6 weeks ago - U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract - GlobeNewsWire
- 2 months ago - Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale - GlobeNewsWire
- 2 months ago - Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment - GlobeNewsWire
- 3 months ago - Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method - GlobeNewsWire
- 4 months ago - Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences - GlobeNewsWire
- 4 months ago - Pluri Inc. Announces 1-for-8 Reverse Share Split - GlobeNewsWire